UPC_CFI_1/2023

ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

NichtigkeitHauptnichtigkeitsklageMunich CDRevocationCase Closed

Übersicht Entscheidungen Begründung Zitate Dokumente Zeitverlauf

Parteien

Kläger

Sanofi-Aventis Deutschland GmbH(Sanofi Group)

Vertreter: Daniel Wise

Beklagte

Amgen Inc.(Amgen Group)

Vertreter: Koen Bijvank

Richter

Ulrike Voß
Andras Kupecz
Casper Struve

Patente

EP3666797
EP 3 666 797

CPC-Codes: C07K2317/14, C07K2317/34, A61K39/395, A61K2039/505, A61K31/366, A61P3/06, A61K31/66, A61K31/22, A61P9/00, A61P7/00, A61P25/28, A61K2300/00…

Technologiebereich: Biotech · Antibody

Sektor: Biotechnology

Ausgang

Nichtig erklärtVollständig nichtig

Eingereicht: 2. Juni 2023

Erste Entscheidung: 29. Juni 2023

Letzte Entscheidung: 24. Feb. 2024

Sprache: English

The Munich Central Division (UPC's first-ever revocation case) revoked European patent EP 3 666 797 B1 (relating to an anti-PCSK9 antibody composition for treating hypercholesterolaemia, owned by Amgen) in its entirety for the territories of 17 UPC Contracting Member States. The patent was found to lack inventive step. All 17 auxiliary requests were also found to lack inventive step. Amgen (defendant/patent proprietor) was ordered to bear Sanofi's legal costs of EUR 1,375,000.

Im UPC-Register öffnen

Ansprüche

Streitigall

Nichtig erklärtall

Hinweise: EP 3 666 797 B1 revoked entirely (UPC's first revocation case); Main Request and all 17 Auxiliary Requests lacked inventive step.